US Stock MarketDetailed Quotes

CTXR Citius Pharmaceuticals

Watchlist

3.3000
+0.0400+1.23%

Close Jan 17 16:00 ET

3.1800
-0.1200-3.64%

Post 19:55 ET

28.36MMarket Cap-0.55P/E (TTM)

Citius Pharmaceuticals Stock Forum

Stock_Drift

Jan 7 07:28

$Citius Pharmaceuticals (CTXR.US)$

Teddy123

Jan 7 07:24

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

$Citius Pharmaceuticals (CTXR.US)$
Citius Pharmaceuticals Advances LYMPHIR Launch Plans for Breakthrough CTCL Treatment

News

NEWS

$Citius Pharmaceuticals (CTXR.US)$ $Citius Oncology (CTOR.US)$
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Tuesday, 7th January at 8:08 am
CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR) and its oncology-focused subsidiary, Citius Oncology (NASDAQ: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an i...

Teddy123

Jan 6 06:54

Serious pursuit of strategic options

$Citius Pharmaceuticals (CTXR.US)$
The engagement of Jefferies as a financial advisor is a strategically significant move that could reshape Citius Oncology's future. Jefferies' strong track record in healthcare M&A and their expertise in orchestrating deals averaging $500M-$2B in the biotech sector positions them well to explore value-maximizing opportunities. With LYMPHIR™ recently FDA-approved and ready for commercialization, the timing aligns perfectly with...

Jaguar8

Jan 6 06:50

NEWS

$Citius Pharmaceuticals (CTXR.US)$
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Monday, 6th January at 7:50 am
CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategi...